Obesity is associated with both endoplasmic reticulum (ER) stress and chronic metabolic inflammation. ER stress activates the unfolded protein response (UPR) and has been implicated in a variety of cancers, including hepatocellular carcinoma (HCC). It is unclear whether individual UPR pathways are mechanistically linked to HCC development, however. Here we report a dual role for inositol-requiring enzyme 1a (IRE1a), the ER-localized UPR signal transducer, in obesity-promoted HCC development. We found that genetic ablation of IRE1a in hepatocytes not only markedly reduced the occurrence of diethylnitrosamine (DEN)-induced HCC in liver-specific IRE1a knockout (LKO) mice when fed a normal chow (NC) diet, but also protected against the acceleration of HCC progression during high-fat diet (HFD) feeding. Irrespective of their adiposity states, LKO mice showed decreased hepatocyte proliferation and signal transducer and activator of transcription 3 (STAT3) activation, even in the face of increased hepatic apoptosis. Furthermore, IRE1a abrogation blunted obesity-associated activation of hepatic inhibitor of nuclear factor kappa B kinase subunit beta (IKKb)-nuclear factor kappa B (NF-jB) pathway, leading to reduced production of the tumorpromoting inflammatory cytokines tumor necrosis factor (TNF) and interleukin 6 (IL-6). Importantly, higher IRE1a expression along with elevated STAT3 phosphorylation was also observed in the tumor tissues from human HCC patients, correlating with their poorer survival rate. Conclusion: IRE1a acts in a feed-forward loop during obesity-induced metabolic inflammation to promote HCC development through STAT3-mediated hepatocyte proliferation. (HEPATOLOGY 2018; 68:533-546).
H epatocellular carcinoma (HCC) is the major form of primary liver cancer, and is the second leading cause of cancer deaths, owing to its poor 5-year survival rate.
(1) The initiation and malignant progression of HCC rely upon the complex interactions between genetic, environmental, and lifestyle factors. Human epidemiological studies have established overweight and obesity as profound carcinogenic risk factors, (2) and an up to 4.5-fold increase in relative HCC risk has been documented in male
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A great majority of HCC develops in the context of chronic liver damage arising from exposure to carcinogens, hepatitis viral infections, and nonalcoholic steatohepatitis (NASH). (6) NASH is a severe stage of nonalcoholic fatty-liver disease (NAFLD) that is highly associated with obesity. (7) Recent studies have revealed several potential mechanisms for the HCC-promoting impact of obesity and NAFLD, including inflammation, endoplasmic reticulum (ER) stress, and oxidative stress. (8) (9) (10) (11) (12) (13) Proinflammatory cytokines, particularly tumor necrosis factor (TNF) and interleukin 6 (IL-6), whose circulating levels are typically elevated in obesity, (14) have been shown to play pivotal roles in obesity and NASH promotion of carcinogen-induced HCC development. (9) Moreover, both ER and oxidative stresses are known to induce hepatocyte death, resulting in liver damage that stimulates the compensatory proliferation of differentiated hepatocytes. (10, 11) During this process, activation of nuclear factor kappa b kinase subunit beta (IKKb)-nuclear factor kappa b (NF-jB) as well as signal transducer and activator of transcription 3 (STAT3) in initiated hepatocytes is thought to drive the malignant progression of HCC. (8, 9) Notably, in chemical carcinogen diethylnitrosamine (DEN)-induced HCC mouse models, TNF signaling was shown to be critical in the promotion by obesity and ER stress of HCC development under the condition of overnutrition (9, 10) ; however, loss of hepatocyte inhibitor of nuclear factor kappa b kinase subunit beta (IKKb) or NF-jB, the downstream component of the canonical TNF pathway, was reported to enhance chemical hepatocarcinogenesis in the absence of obesity. (11, 12, 15) Thus, it remains largely obscure whether there exist common mechanisms linking obesity, ER stress, and hepatic inflammatory microenvironment to the malignant progression of HCC.
Perturbations of the ER function as a result of excessive accumulation of unfolded/misfolded proteins or alterations in ER lipid compositions lead to ER stress and activation of the adaptive unfolded protein response (UPR). (16, 17) Three ER-localized transmembrane signal transducers, inositol-requiring enzyme 1 (IRE1), PKRlike endoplasmic reticulum kinase (PERK), and activating transcription factor 6 (ATF6), function to govern the cellular UPR program. (16) Persistent activation of these ER stress sensors is thought to confer a greater tumorigenic capacity upon malignant cells. (18, 19) Although both metabolic ER stress and chronic inflammation have been found in the state of obesity, (20) (21) (22) it has yet to be dissected if individual UPR branches are directly involved in promoting liver damage, inflammation, and compensatory proliferation during HCC development in the face of obesity. In particular, IRE1 is the most conserved ER stress sensor that possesses both Ser/Thr kinase and endoribonuclease activities. (23) Upon ER stress, IRE1 is activated through autophosphorylation and dimerization/ oligomerization, and regulates the non-conventional splicing of X-box binding protein 1 (Xbp1) mRNA or degrades a select subset of mRNAs via a process termed regulated IRE1-dependent decay (RIDD). (23) Our previous studies in mouse models have revealed that hepatic inositol-requiring enzyme 1a (IRE1a) is hyperactivated in the state of obesity, (24, 25) and it has an important role during reparative liver regeneration. (26) Here we investigated whether IRE1a is able to connect metabolic ER stress to promotion of hepatocyte proliferation and HCC
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development during overnutrition-induced obesity. We found that IRE1a expression correlated with human HCC, and through its impact upon both the IKKb-NFjB and STAT3 pathways, IRE1a could exert dual actions in obesity acceleration of carcinogen-induced HCC development.
Materials and Methods

ANIMALS
Liver-specific IRE1a knockout (LKO) mice on the C57BL/6 background were generated by intercrossing the endoplasmic reticulum to nucleus signaling 1 (Ern1) floxed (flox/flox) mice, in which the exon 2 of the Ern1 allele was flanked by loxP sites, with the Albcre mice as described. (26, 27) All other materials and methods are described in Supplemental Information.
STATISTICAL ANALYSIS
Data are presented as the mean 6 standard errors of the mean (s.e.m.). Statistical analysis was conducted using unpaired two-tailed t-test, one-way or two-way analysis of variance (ANOVA), followed by Bonferroni's post hoc tests with GraphPad Prism 5.0. P<0.05 was considered statistically significant.
Results
ABLATION OF HEPATOCYTE IRE1a PROTECTS AGAINST OBESITY-PROMOTED HCC DEVELOPMENT
Overnutrition has been reported to promote DENinduced or ER stress-evoked hepatic tumorigenesis in mice maintained on an HFD. (9, 10) In accordance with these studies, we also observed markedly increased incidence of HCC in DEN-treated male mice following 24 weeks of HFD feeding when compared to those fed a normal chow (NC) diet ( Fig. S1A-C) . Moreover, immunoblot analysis revealed significantly higher phosphorylation levels of hepatic IRE1a, PERK and eukaryotic translation initiation factor 2 alpha (eIF2a), and elevated expression levels of BiP, in parallel with prominently increased phosphorylation activation of the oncogenic transcription factor STAT3, in livers of HFD-fed DEN-treated mice (Fig. S1D ). Phos-tag gel analysis of IRE1a ( Fig. S1E ) and RT-PCR assessment of Xbp1 mRNA splicing (Fig. S1F ) further affirmed higher activation of liver IRE1a in HFD-fed animals. Thus, during obesity promotion of DEN-induced tumorigenesis, HFD feeding results in hyperactivation of hepatic IRE1 and PERK pathways of the UPR that accompanied increased STAT3 activation. This indicates a potential link between sustained activation of the ER stress sensors and acceleration of HCC progression.
Given that IRE1a activation was increased in livers of HFD-fed HCC-bearing mice, we employed the LKO mouse model (26, 27) to test if hepatocyte IRE1a contributed to the promotion of HCC progression during overnutrition. Intriguingly, following a shortterm HFD feeding of 16 weeks, we observed lower liver weight (an indicator of tumor burden) and reduced DEN-induced HCC incidence in male LKO mice than in flox/flox control mice ( Fig. S2A-C ). After 24 weeks of feeding, while no HCC tumors were detectable in NC-fed DEN-treated mice, loss of IRE1a markedly blunted HFD-induced development of HCC in LKO mice without affecting their body weight gain as compared to their flox/flox counterparts ( Fig. 1A-C) . Quantitative analyses revealed that HFD-fed LKO mice had significantly decreased liver weight (by 40% [ Fig. 1D] ) and markedly reduced total number (by 67%) and maximal size (by 50%) of visible HCC tumors (Fig. 1E ). Further distribution assessment showed that the number of various tumor sizes was significantly decreased in LKO mice (Fig.  1F ). These results suggest that abrogation of IRE1a in hepatocytes hinders the acceleration of DEN-induced HCC development in the state of dietary obesity.
ABROGATION OF HEPATOCYTE IRE1a SUPPRESSES CHEMICAL TUMORIGENESIS IN LEAN MICE
Next, we asked if IRE1a is directly involved in DEN-induced tumorigenesis in the absence of overnutrition-induced obesity. When maintained on an NC diet and examined at 40 weeks after DEN administration, lower incidence of HCC was detected in LKO mice relative to their flox/flox control animals ( Fig. 2A-C) . Quantitative analysis showed that LKO mice had a 30% reduction in their liver weight (Fig.  2D ) and significant decreases in the number (by 50%) and maximal size (by 50%) of HCC tumors (Fig. 2E) . Distribution assessment also revealed significantly fewer HCC tumors of various sizes (Fig. 2F) . Thus, IRE1a in hepatocytes plays a critical role in carcinogen-induced liver tumorigenesis in addition to mediating the promoting effect of obesity upon HCC progression during overnutrition.
HEPATOCYTE IRE1a ABLATION RESULTS IN ENHANCED HEPATIC APOPTOSIS
To explore the mechanisms by which hepatocyte IRE1a exerts its tumor-promoting effect, we first examined if loss of IRE1a could lead to alterations in hepatic ER stress and cell death that may account for the decreased susceptibility of LKO mice to hepatocarcinogenesis. Short-term DEN administration induced an acute hepatic UPR activation in flox/flox control mice, as indicated by elevations in eIF2a phosphorylation, BiP protein expression, Xbp1 mRNA splicing, as well as the mRNA abundance of C/EBP homologous protein (Chop) and its target gene death receptor 5 (Dr5), (16, 28) and IRE1a deficiency further enhanced these ER stress markers in LKO mice except Xbp1 mRNA splicing (Fig. S3A-C) . At 8 weeks after DEN injection when no HCC tumors were detectable in mice maintained either on NC or HFD, LKO livers showed significantly increased PERK and eIF2a phosphorylation levels despite of decreased PERK protein abundance (Fig. 3A) , while exhibiting no significant changes in BiP protein levels. Because hyperactivation of the PERK-eIF2a branch is known to trigger ER stress-associated apoptosis through the activating transcription factor 4 (ATF4)-CHOP cascade, (16, 19, 28) we measured the mRNA abundance of Atf4, Chop, and two CHOP target genes, Dr5 and Tribbles homolog 3 (Trb3), as well as DR5 protein level, which was all elevated in LKO livers (Fig. 3A, B) . These results indicate that loss of IRE1a could cause an overactivation of the PERK-eIF2a branch in DEN-treated livers, leading to enhanced activation of the apoptotic CHOP pathway. (19) Indeed, TUNEL analyses revealed that LKO mice, regardless of NC or HFD feeding after DEN injection, had significantly increased apoptotic cells in their livers relative to their flox/flox counterparts (Fig. 3C) . Consistently, the anti-apoptotic protein Bcell lymphoma 2 (BCL2) decreased, while the cleaved active form of apoptotic Caspase 3 (c-Caspase 3) increased in LKO livers (Fig. 3D) . Moreover, in NCfed mice at 40 weeks and HFD-fed mice at 24 weeks after DEN injection when HCC tumors were easily detectable ( Fig. 1) , we detected in HFD-fed animals significantly elevated hepatic Xbp1 mRNA splicing but an insignificant alteration in the mRNA level of biogenesis of lysosomal organelles complex-1, subunit 1 (Bloc1s1) (Fig. S4A) , a typical RIDD target gene whose cleavage can be temporally separate from Xbp1 mRNA splicing. (29, 30) Whether fed an NC or an HFD, loss of IRE1a led to markedly reduced Xbp1 mRNA splicing without a significant change in the mRNA abundance of Bloc1s1 (Fig. S4A) , and resulted in similarly enhanced activation of the PERK-eIF2a branch and increased apoptosis in LKO livers (Fig. S4B,C) . Thus, it is possible that the enhanced cell death in LKO livers, if occurring in initiated hepatocytes, might contribute to the protective effect of IRE1a abrogation during DENinduced tumorigenesis. However, hepatocyte death has been largely documented to stimulate the compensatory proliferation that promotes chemical carcinogenesis in several mouse HCC models. (10) (11) (12) Therefore, it is more likely that loss of IRE1a could suppress HCC development through other more predominant mechanisms such as blocking the compensatory proliferation of hepatocytes, even in the face of increased hepatic cell death.
HEPATOCYTE IRE1a ABROGATION IMPEDES HEPATOCYTE PROLIFERATION THROUGH BLUNTING STAT3 ACTIVATION
We then examined the impact of IRE1a deficiency upon hepatocyte proliferation. Indeed, immunostaining analyses revealed markedly reduced Ki-67-, PCNA-and K19-positive cells in LKO livers from DEN-treated mice when maintained on NC for 40 weeks or on HFD for 24 weeks relative to their flox/flox counterparts (Fig.  4A-C) , suggesting decreased hepatocyte proliferation as a result of IRE1a ablation. Given the critical role of persistent STAT3 activation in driving the proliferation and survival of HCC tumor cells, (9, 10, 13, 31, 32) we determined the activation states of STAT3. Immunoblot analysis showed that HFD feeding increased the tyrosine phosphorylation levels of hepatic STAT3 in flox/flox mice. By contrast, LKO livers exhibited substantially decreased STAT3 phosphorylation irrespective of NC or HFD feeding (Fig. 4D) . Consistently, HFD feeding significantly increased liver mRNA abundance of STAT3 target genes involved in regulating cellular proliferation, myelocytomatosis oncogene (c-Myc), FBJ osteosarcoma B-cell lymphoma oncogene (c-Fos) and hypoxia inducible factor 1, alpha subunit (Hif1a), which were prominently reduced in NC-or HFD-fed LKO mice (Fig. 4E) . These results indicate that IRE1a acts to promote hepatocyte proliferation and HCC progression through maintaining the activation of the STAT3 pathway, supporting our previous finding that IRE1a could interact with STAT3 and sustain its activation during reparative liver regeneration. (26) To gain insight into the mechanism for IRE1a regulation of STAT3 activation, we utilized chemical inhibitors of IRE1a. Interestingly, blocking IRE1a's kinase activity by KIRA6 not only reduced the ER stressor tunicamycin-induced IRE1a phosphorylation and Xbp1 splicing, but also blunted IL-6-stimulated STAT3 phosphorylation in a dose-dependent manner in HepG2 cells (Fig. S5A) . By contrast, inhibition of its RNase activity by 4l8C did not show a discernable effect on STAT3 phosphorylation (Fig. S5B) . These data further suggest that IRE1a's kinase, but not RNase, activity may be critical in regulating the activation status of STAT3, in accordance with our reported study showing that IRE1a's kinase but not RNase domain is required for interacting with STAT3. (26) 
HEPATIC IRE1a DEFICIENCY ALLEVIATES HFD-INDUCED HEPATOSTEATOSIS AND METABOLIC INFLAMMATION
We further investigated whether hepatocyte IRE1a abrogation prevented obesity-induced acceleration of HCC progression through affecting liver steatosis and metabolic inflammation. HFD feeding for 4 weeks following DEN treatment resulted in higher hepatic lipid and triglyceride levels relative to NC feeding in flox/flox mice, and IRE1a ablation significantly reduced this HFD-induced liver steatosis in LKO mice (Fig. 5A,B) . HFD feeding in flox/flox mice also led to increased serum and hepatic levels of TNFa and IL-6, which were significantly blunted in LKO animals (Fig. 5C,D) . Given NF-jB as the classical transcriptional regulator that drives the expression of numerous cytokines and chemokines to maintain the tumor-promoting inflammatory microenvironment, (9) we examined its activation state in the livers of DEN-treated mice. Indeed, IRE1a ablation blunted HFD-induced increases in hepatic P65 phosphorylation and Il-6 mRNA abundance in LKO mice (Fig. 5E,F) . These data suggest that hepatocyte IRE1a serves as a crucial promoter of obesityassociated metabolic inflammation to further enhance the IL-6-STAT3 pathway, thus contributing to the acceleration of HCC progression in the state of obesity.
HEPATOCYTE IRE1a MEDIATES HFD-INDUCED ACTIVATION OF THE IKKb-NF-jB PATHWAY
TNF receptor signaling has been shown to be required for obesity-or ER stress-promoted HCC development. (9, 10) Thus, we wondered if IRE1a could link overnutrition-induced obesity to hepatic activation of the canonical TNF signaling cascade, i.e., the IKKb-NF-jB pathway, in DEN-treated mice. When maintained on an NC diet, hepatocyte IRE1a ablation showed no effects upon the phosphorylation of IKKb, IjBa and P65, as well as the protein level of IjBa, in livers of DEN-treated LKO mice relative to their flox/ flox counterparts (Fig. 6A) . By contrast, following 4 weeks of HFD feeding, DEN-treated LKO livers exhibited marked reductions in the phosphorylation of IKKb, IjBa and P65, along with an increase in IjBa protein level (Fig. 6A) . Consistently, increased cytoplasmic accumulation and decreased nuclear level of P65 protein were seen in LKO livers following HFDfeeding (Fig. 6B) . These data indicate that hepatocyte IRE1a abrogation leads to suppression of obesityassociated activation of hepatic IKKb-NF-jB pathway.
Then we examined whether IRE1a was able to mediate TNF activation of the IKKb-NF-jB pathway in a cell-autonomous fashion. NF-jB-activated luciferase reporter assays showed that siRNA knockdown of the expression of IRE1a substantially diminished the stimulation by recombinant TNFa of NF-jB transcription activity in HepG2 cells (Fig. 6C) .
Consistently, IRE1a deficiency resulted in marked suppression of TNFa-induced phosphorylation of IKKb, IjBa and P65, along with elevated protein level of IjBa in HepG2 cells (Fig. 6D) . However, siRNA knockdown of XBP1 expression (Fig. S6A ) had no effect on TNFa-stimulated transcriptional activation of NF-jB (Fig. S6B) , and did not alter the phosphorylation state of IKKb, IjBa or P65 while causing an appreciable elevation of IRE1a phosphorylation (Fig.  S6C ). These results demonstrate that IRE1a is coupled to TNF signaling to promote NF-jB activation 48 hours with the NF-jB-luciferase reporter plasmid along with two siRNAs directed against IRE1a or a scramble control. Cells were then treated with TNFa (10 ng/ml) for 24 hours, and NF-jB activity was determined by the luciferase assay. Shown are relative luciferase activities after normalization to Renilla that was used as the internal control. (D) HepG2 cells were likewise transfected with the two IRE1a siRNAs and then treated with TNFa (10 ng/ml) for the indicated time intervals. Phosphorylation of IKKb, IjBa and P65 proteins was analyzed and shown after normalization to the value of the untreated control cells (n54 independent experiments). All data are presented as the mean 6 s.e.m., *P < 0.05, **P < 0.01, ***P<0.001 by two-tailed unpaired Student's t-test or two-way ANOVA.
without requiring XBP1 during metabolic inflammation, which most likely resembles the experimental ER stress state giving rise to IRE1a-directed activation of NF-jB. (33, 34) 
HIGHER IRE1a EXPRESSION CORRELATES WITH STAT3 ACTIVATION IN HUMAN HCC
To understand the clinical relevance of IRE1a in human HCC, we examined the expression of IRE1a in matched non-tumor and tumor samples from HCC patients. Remarkably, we detected higher IRE1a protein levels in nearly all of the 12 HCC tumor samples as compared to their non-tumor control tissues (Fig. 7A) . We then analyzed the relationship between tumor IRE1a expression, STAT3 phosphorylation and the overall survival of HCC patients by tissue microarray (TMA) analysis of 94 HCC patients. TMA assessment also revealed elevated levels of IRE1a protein, as well as higher phosphorylation of STAT3 in HCC tumors relative to their matched non-tumor tissues (Fig. 7B) . Moreover, higher extent of elevations in IRE1a protein levels and in STAT3 activation states significantly correlated with decreased overall survival rate in 18 and 32 HCC patients, respectively (Fig. 7C) . Linear regression analysis also revealed an appreciable association between IRE1a protein and STAT3 activation (r 2 50.409, p<0.0001) in human HCC (Fig. 7D) . These results suggest that IRE1a indeed represents an important aspect linking the UPR activation to the malignant development of human HCC through the STAT3 pathway. 
Discussion
Persistent activation of the UPR pathways is thought to enable cancer cells to better cope with hostile environments and thus has an important role in promoting tumorigenesis. (18) Chronic ER stress in metabolic organs is a common feature in obesity, (20) but it remains unclear whether the IRE1a branch of the UPR links obesity-associated inflammation to the promotion of chemical carcinogenesis in the liver. Utilizing a mouse HCC model, this study reveals that during HFDinduced obesity, IRE1a in hepatocytes have multifaceted actions in accelerating the malignant progression of HCC. On one hand, hepatocyte IRE1a promotes obesity-associated activation of the IKKb-NF-jB pathway, which leads to increased hepatic production of typical pro-inflammatory cytokines such as IL-6; on the other hand, hepatocyte IRE1a serves to maintain the activation of STAT3, thus promoting hepatocyte proliferation. Given that the IL-6-STAT3 pathway is essential in hepatocyte proliferation during obesity-promoted hepatocarcinogenesis, (9, 10) our results uncover a critical IRE1a-mediated feed-forward loop for accelerating HCC development through STAT3-promoted proliferation in the context of overnutrition-induced obesity and metabolic inflammation.
Our findings highlight the crucial IRE1a-STAT3 axis in promoting the malignant progression of HCC regardless of the adiposity states. Following DEN administration, hepatocyte IRE1a ablation resulted in diminished STAT3 activation along with reduced hepatocyte proliferation, thus protecting against HCC development not only in HFD-fed obese mice, but also in NC-fed lean mice. This is congruent with our previous finding that hepatic IRE1a could directly interact with STAT3 to maintain its activation, thereby promoting reparative liver regeneration after tissue damage. (26) STAT3 is the oncogenic transcription factor that is central in regulating the proliferation and survival of tumor cells, (9, 10, 13, 31) and frequent activation of STAT3 has been documented in human HCCs with poor prognosis. (35) Many studies have also established that STAT3 can be activated in cancer by a myriad of cellular pathways in addition to IL-6 and its family members. (31) Although the precise mechanism by which IRE1a controls STAT3 activation remains to be deciphered, IRE1a's kinase activity appeared to be involved. Targeted disruption of IRE1a-STAT3 association may block the STAT3 pathway and prevent the progression of HCC, even in the absence of obesity and metabolic inflammation.
Both TNFa and IL-6 signaling pathways have been found to be important in mediating the HCCpromoting effects of obesity and ER stress. (9, 10) Our results also reveal that hepatocyte IRE1a is coupled to metabolic inflammation through enhancing TNFa activation of the IKKb-NF-jB cascade. IRE1a was reported to associate with TNF-receptor-associated factor 2 (TRAF2) (36) and form a complex with IKKb through TRAF2 to mediate NF-jB activation during experimental ER stress. (33, 34) Recent reported studies also suggested that IRE1a's kinase activity was involved in maintaining the basal activity of IKKb. (37, 38) It is likely that during obesity-associated metabolic ER stress, IRE1a could enhance activation of the IKKb-NF-jB cascade in hepatocytes through similar mechanisms, leading to higher hepatic production of IL-6 and presumably other inflammatory mediators as well. (39, 40) While IRE1a ablation resulted in reduced hepatic levels of TNFa and IL-6 during dietary obesity, we did not detect apparent changes in macrophages or T cells from HCC tumors (data not shown). However, it has yet to be further investigated whether IRE1a-deficient hepatocytes could affect the infiltrated immune cells with regard to their capacity of cytokine production to maintain the inflammatory microenvironment in the liver throughout the process of HCC progression. Nevertheless, the reduced production of IL-6 in IRE1a-deficient livers could be a key contributor in diminishing its autocrine activation of STAT3 to blunt the acceleration of HCC in the face of dietary obesity.
It is worth noting that hepatocyte IRE1a ablation resulted in alleviation of hepatosteatosis and liver inflammation during HFD feeding but led to increased cell death that could be ascribed to hyperactivation of the PERK-eIF2a pathway and/or deficient STAT3 activation in both obese and lean mice. Whereas enhanced apoptosis in transformed hepatocytes of DEN-treated LKO mice might contribute in hindering the progression of HCC, it is more likely that such increased apoptosis was unable to trigger the compensatory proliferation of hepatocytes (41, 42) owing to the impairment of STAT3 activation in IRE1a-deficient hepatocytes. Of interesting note, we also observed a reduction of PERK protein abundance despite of its higher phosphorylation level in IRE1a-deficient hepatocytes. This suggests a possible, as-yet-unrecognized interconnection between these two UPR branches in this particular experimental context. Moreover, given its roles in hepatic lipid metabolism, (27, 43) it remains to be fully understood whether the IRE1a-XBP1 branch contributed to, or the IRE1a-STAT3 axis was also involved in, overnutrition-associated hepatosteatosis during obesity-promoted HCC progression.
Finally, we have found high levels of IRE1a expression in association with human HCC tumors, which appreciably correlated with increased STAT3 activation and poorer survival rate of the examined patients. It remains to be dissected, however, what exact activation features enable IRE1a to promote STAT3 activation in human HCC. Interestingly, human cancer genome studies of HCC have uncovered a number of somatic mutations within ERN1, the human gene encoding IRE1a. (44, 45) Further functional investigations are warranted to delineate the potential impact of these mutations upon its role in maintaining the persistent activation of STAT3 and NF-jB in human HCC, whether it is associated with higher risks endowed by obesity, NASH, or HBV/HCV infection. In short, our work demonstrates a crucial tumorpromoting activity of IRE1a in HCC development. A variety of human cancer has been documented to have increased ER stress. (19) Given the essential importance of STAT3 and NF-jB in other inflammationassociated cancers, (9, (46) (47) (48) (49) (50) IRE1a may contribute to the malignant progression of other types of tumor as well. Targeted blocking of the molecular connections between IRE1a and STAT3 or IKKb may bear promising translational potentials for the development of therapeutics against not only HCC but also many other malignancies.
